抗α-1C微管蛋白抗体在系统性硬化症中的表达及临床意义

doi:10.19723/j.issn.1671-167X.2020.06.004

摘要/Abstract

摘要：

目的:检测抗α-1C微管蛋白(tubulin-α-1C)抗体在系统性硬化症(systemic sclerosis, SSc)患者血清中的表达,并探讨其潜在的临床意义。方法:入组SSc患者62例、系统性红斑狼疮(systemic lupus erythematosus, SLE)患者38例、原发性干燥综合征(primary Sj?gren’s syndrome, pSS)患者24例和健康对照组(health control, HC)30例,收集血清,采用酶联免疫吸附试验(enzyme linked immunosorbent assay, ELISA)分别检测各组血清中抗tubulin-α-1C抗体水平。同时,用标准实验室技术测定红细胞沉降率(erythrocyte sedimentation rate, ESR)、C反应蛋白(C-reactive protein, CRP)、免疫球蛋白A(Immunoglobulin A, IgA)、免疫球蛋白M(Immunoglobulin M, IgM)、免疫球蛋白G(Immunoglobulin G, IgG)、补体C3、补体C4、类风湿因子(rheumatoid factor, RF)、抗核抗体(antinuclear antibody, ANA)、抗着丝点抗体(anti-centromere antibodies, ACA)、抗心磷脂抗体(anticardiolipin, aCL)、抗双链DNA抗体(抗dsDNA抗体)、抗Sm抗体、抗RNP抗体、抗Scl-70抗体、抗Ro-52抗体、抗SSA抗体、抗SSB抗体、着丝点蛋白A(centromere protein A,CENP-A)、着丝点蛋白B(centromere protein B,CENP-B)等指标。记录雷诺现象和改良的Rodnan评分(modified Rodnan skin score, MRSS)等临床表现来评估SSc的疾病状态,分析抗tubulin-α-1C抗体与其他实验室指标和临床表现的关系。组间计量资料比较采用两独立样本t检验或Mann-Whitney U检验;组间计数资料比较采用卡方检验;采用绘制实验组工作曲线确定抗tubulin-α-1C抗体对诊断SSc最佳截断值并分析其诊断效能,相关性分析采用Spearman相关分析。结果:SSc患者、SLE患者、pSS患者和正常对照组血清中抗tubulin-α-1C抗体水平分别为81.24±34.38、87.84±38.52、59.79±25.24、39.37±18.7,SSc患者血清抗tubulin-α-1C抗体水平显著高于pSS患者和正常对照组,P均小于0.001。SSc患者血清抗tubulin-α-1C抗体水平与SLE组差异没有统计学意义。Spearman相关性分析示抗tubulin-α-1C抗体与SSc炎症和疾病活性标志物ESR正相关(r=0.313,P=0.019),与MRSS正相关(r=0.636, P<0.01)。根据正常对照组表达抗tubulin-α-1C抗体$\bar{x}+2s$定义阳性阈值为76.77,将SSc患者分为抗tubulin-α-1C抗体阳性组和阴性组,抗tubulin-α-1C抗体阳性组出现雷诺现象的比例明显高于阴性组(71.4% vs. 37.5%,P=0.039); 抗tubulin-α-1C抗体阳性组中抗Scl-70抗体、ACA抗体和aCL抗体的阳性率也显著高于阴性组(分别为37.9% vs. 15.2%,P=0.041; 34.5% vs. 12.1%, P=0.035; 13.8 vs. 0, P=0.027)。结论:抗tubulin-α-1C抗体在SSc患者血清中异常升高,可能成为一种新的生物标志物用于SSc的临床诊断和风险预测。

关键词: 系统性硬化症, 抗α-1C微管蛋白抗体, 自身抗体

Abstract:

Objective: To detect the serum level of a novel autoantibody, anti-tubulin-α-1C, in patients with systemic sclerosis (SSc) and to investigate its clinical significance. Methods: Anti-tubulin-α-1C antibody levels were determined by enzyme-linked immunosorbent assay (ELISA) in 62 patients with SSc, 38 systemic lupus erythematosus (SLE), 24 primary Sj?gren’s syndrome (pSS) patients, and 30 healthy controls (HCs). Erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), immunoglobulin A(IgA), immunoglobulin M (IgM), immunoglobulin G (IgG), C3, C4, rheumatoid factor (RF), antinuclear antibody(ANA), anti-centromere antibodies( ACA), anticardiolipin (aCL), anti-dsDNA antibody, anti-Sm antibody, anti-RNP antibody, anti-Scl-70 antibody, anti-Ro52 antibody, anti-SSA antibody, anti-SSB antibody, centromere protein A(CENP-A), centromere protein B (CENP-B) were measured by standard laboratory techniques. Raynaud’s phenomenon and modified Rodnan skin score(MRSS) were recorded to evaluate the disease status of SSc. Independent sample t test, Chi square test, Mann-Whitney U test, Spearman rank correlation were used for statistical analyses. Results: The serum anti-tubulin-α-1C antibody concentration in SSc group was 81.24±34.38, the serum anti-tubulin-α-1C antibody concentration in SLE group was 87.84±38.52, the serum anti-tubulin-α-1C antibody concentration in pSS group was 59.79±25.24, and the serum anti-tubulin-α-1C antibody concentration in healthy group was 39.37±18.7. Multivariate analysis revealed that anti-tubulin-α-1C antibody levels were significantly increased in the SSc and SLE patients. The expression level of anti-tubulin-α-1C antibody in SSc was higher compared with the pSS group and the health control group (P<0.01). Further analysis demonstrated that the elevated anti-tubulin-α-1C antibody were correlated with the SSc inflammation and disease activity markers ESR(r=0.313, P=0.019), The levels of anti-tubulin-α-1C antibody were also significantly correlated with MRSS(r=0.636, P<0.01). The best cut-off value for the diagnose of SSc was 76.77 as mean+2SD value. The proportion of Raynaud's phenomenon was higher in the group of anti-tubulin-α-1C autoantibody-postive SSc patients than that in anti-tubulin-α-1C autoantibody negative group(71.4% vs. 37.5%, P=0.039). The proportions of anti-Scl-70 antibody, anti-CENP antibody and anti-cardiolipin antibody were higher in the group of anti-tubulin-α-1C autoantibody-postive SSc patients than in the anti-tubulin-α-1C autoantibody negative group (37.9% vs. 15.2%, 34.5% vs. 12.1%, 13.8 vs. 0, respectively, all P<0.05). Conclusion: Based on this explorative stu-dy, the level of anti-tubulin-α-1C antibody increased in the serum of the patients with SSc. There were correlations between anti-tubulin-α-1C autoantibody and clinical and laboratory indicators of the SSc patients. It may become a novel biomarker indicative of active SSc and could be applied in future clinical practice.

Key words: Systemic sclerosis, Anti-tubulin-α-1C antibody, Autoantibodies

中图分类号:

R783.2

赵静,孙峰,李云,赵晓珍,徐丹,李英妮,李玉慧,孙晓麟. 抗α-1C微管蛋白抗体在系统性硬化症中的表达及临床意义[J]. 北京大学学报（医学版）, 2020, 52(6): 1009-1013.

Jing ZHAO,Feng SUN,Yun LI,Xiao-zhen ZHAO,Dan XU,Ying-ni LI,Yu-hui LI,Xiao-lin SUN. Significance of anti-tubulin-α-1C autoantibody in systemic sclerosis[J]. Journal of Peking University (Health Sciences), 2020, 52(6): 1009-1013.

图/表 2

表1

抗tubulin-α-1C抗体阳性组与阴性组间实验室指标的比较"

Items	Anti-tubulin-α-1C(+)(n=29)	Anti-tubulin-α-1C(-)(n=33)	P
Female, n(%)	26 (89.7)	31 (93.9)	0.537
Age/years, $x - ± s$	59.07±20.42	51.88±10.45	0.081
ESR /(mm/h), M(Min, Max)	21 (7-110)	12 (2-55)	0.033^*
CRP/(mg/L), M(Min, Max)	2.49 (0.54-73.90)	2.95 (0.38-44.21)	0.431
C3/(g/L), $x - ± s$	0.87±0.23	0.87±0.26	0.966
C4/(g/L), $x - ± s$	0.22±0.09	0.24±0.26	0.667
RF/(IU/mL), M(Min, Max)	20 (20-123)	20 (18-3 710)	0.781
Anti-Ro52 positive, n(%)	8 (27.6)	16 (48.5)	0.090
Anti-RNP positive, n(%)	7 (24.1)	9 (27.3)	0.780
Anti-Scl-70 positive, n(%)	11 (37.9)	5 (15.2)	0.041^*
ANA positive, n(%)	23 (79.3)	20 (60.6)	0.110
ACA positive, n(%)	10 (34.5)	4 (12.1)	0.035^*
CENP A or B positive, n(%)	6 (20.7)	6 (18.2)	0.803
aCL positive, n(%)	4 (13.8)	0	0.043^*
Anti-dsDNA positive, n(%)	4 (13.79)	1 (3.03)	0.120
IgA/(g/L), $x - ± s$	3.37±2.89	2.52±1.80	0.164
IgG/(g/L), $x - ± s$	15.30±6.61	14.60±6.82	0.681
IgM/(g/L), $x - ± s$	1.17±0.81	0.99±0.70	0.350
Raynaud’s phenomenon, n(%)	15 (71.4)	6 (37.5)	0.039^*

表1

表2

参考文献 17

[1]	Denton CP, Khanna D. Systemic sclerosis[J]. Lancet, 2017,390(10103):1685-1699. doi: 10.1016/S0140-6736(17)30933-9 pmid: 28413064
[2]	Allanore Y, Simms R, Distler O, et al. Systemic sclerosis[J]. Nat Rev Dis Primers, 2015,1:15002 doi: 10.1038/nrdp.2015.2 pmid: 27189141
[3]	Orlandi M, Barsotti S, Lepri G, et al. One year in review 2018: systemic sclerosis[J]. Clin Exp Rheumatol, 2018,113(4):3-23.
[4]	Pattanaik D, Brown M, Postlethwaite BC, et al. Pathogenesis of systemic sclerosiss[J]. Front Immunol, 2015,6:272. doi: 10.3389/fimmu.2015.00272 pmid: 26106387
[5]	Chaaban S, Brouhard GJ. A microtubule bestiary: Structural diversity in tubulin polymerss[J]. Mol Biol Cell, 2017,28(22):2924-2931. doi: 10.1091/mbc.E16-05-0271 pmid: 29084910
[6]	Roll-Mecak A. How cells exploit tubulin diversity to build functional cellular microtubule mosaicss[J]. Curr Opin Cell Biol, 2019,56:102-108. doi: 10.1016/j.ceb.2018.10.009 pmid: 30466050
[7]	Kowal-Bielecka O, Fransen J, Avouac J, et al. Update of EULAR recommendations for the treatment of systemic sclerosis[J]. Ann Rheum Dis, 2017,76(8):1327-1339. doi: 10.1136/annrheumdis-2016-209909 pmid: 27941129
[8]	Avrameas S, Guilbert B, Dighiero G. Natural antibodies against tubulin, actin myoglobin, thyroglobulin, fetuin, albumin and transferrin are present in normal human sera, and monoclonal immunoglobulins from multiple myeloma and Waldenström’s macroglobulinemia may express similar antibody specificities[J]. Ann Immunol (Paris), 1981,132(2):231-236.
[9]	Guilbert B, Dighiero G, Avrameas S. Naturally occurring anti-bodies against nine common antigens in human sera. Ⅰ. Detection, isolation and characterization[J]. J Immunol, 1982,128(6):2779-2787. pmid: 6176652
[10]	Karsenti E, Guilbert B, Bornens M, et al. Anti-actin and anti-tubulin antibodies in the serum of non-immunized animals[J]. Ann Immunol (Paris), 1977,128(1/2):195-200.
[11]	Kurki P, Virtanen I. The detection of human antibodies against cytoskeletal components[J]. J Immunol Methods, 1984,67(2):209-223. pmid: 6200533
[12]	Ludueña RF. A hypojournal on the origin and evolution of tubulin[J]. Int Rev Cell Mol Biol, 2013,302:41-185. doi: 10.1016/B978-0-12-407699-0.00002-9 pmid: 23351710
[13]	Burbelo PD, Gordon SM, Waldman M, et al. Autoantibodies are present before the clinical diagnosis of systemic sclerosis[J]. PLoS One, 2019,14(3):e0214202. pmid: 30913258
[14]	Cheng Y, Zhao X, Chen Y, et al. Circulating immune comple-xome analysis identified anti-tubulin-α-1C as an inflammation associated autoantibody with promising diagnostic value for Behcet’s disease[J]. PLoS One, 2018,13(6):e0199047. doi: 10.1371/journal.pone.0199047 pmid: 29902281
[15]	Zhao X, Cheng Y, Gan Y, et al. Anti-tubulin-α-1C autoantibody in systemic lupus erythematosus: a novel indicator of disease acti-vity and vasculitis manifestationse[J]. Clin Rheumatol, 2018,37(5):1229-1237. doi: 10.1007/s10067-018-4024-3 pmid: 29427009
[16]	Goers TA, Ramachandran S, Aloush A, et al. De novo production of K-alpha1 tubulin-specific antibodies: role in chronic lung allograft rejection[J]. J Immunol, 2008,180(7):4487-4494. pmid: 18354170
[17]	Hachem RR, Tiriveedhi V, Patterson GA, et al. Antibodies to K-α1 tubulin and collagen V are associated with chronic rejection after lung transplantation[J]. Am J Transplant, 2012,12(8):2164-2171. pmid: 22568593

Metrics

Viewed

Full text

Abstract

Cited

Shared

Discussed

Items	r	P
Age/years	0.023	0.860
Disease duration	0.118	0.455
ESR	0.313	0.019^*
CRP	-0.109	0.432
IgA	0.121	0.350
IgG	0.168	0.193
IgM	0.114	0.384
C3	-0.042	0.744
C4	0.086	0.513
RF	-0.079	0.541
aCL	0.330	0.106
Anti-dsDNA	0.146	0.477
MRSS	0.636	<0.001^*